Litigation Details for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Docket		Date Filed	2015-08-24
Court	District Court, E.D. Texas	Date Terminated	2017-10-16
Cause	35:271 Patent Infringement	Assigned To	William C. Bryson
Jury Demand	Both	Referred To
Parties	APOTEX CORP.
Patents	8,501,174; 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930; 9,248,191
Attorneys	Shashank Upadhye
Firms	Naman Howell Smith & Lee PLLC
Link to Docket	External link to docket

Details for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2015-08-24	1	Complaint	U.S. Patent No. 8,629,111, # 3 Exhibit 2 - U.S. Patent No. 8,633,162, # 4 Exhibit 3 - U.S. Patent No. … United States Patent Nos. 8,629,111 (“the ‘111 Patent”), 8,633,162 (“the ‘162 Patent”), 8,642,556 (“…Background A. Patents-In-Suit 1. U.S. Patent No. 8,629,111 73. On…‘556 Patent”), 8,648,048 (“the ‘048 Patent”), and 8,685,930 (“the ‘930 Patent”) under the Patent Laws…8,642,556, # 5 Exhibit 4 - U.S. Patent No. 8,648,048, # 6 Exhibit 5 - U.S. Patent No. 8,685,930)(Hill, Jack)	External link to document
2016-04-19	130	Memorandum & Opinion	several patents relating to RESTASIS— United States Patent Numbers 8,629,111 (“the ’111 patent”), 8,633,162…,162 (“the ’162 patent”), 8,642,556 (“the ’556 patent”), 8,648,048 (“the ’048 patent”), 8,685,930 (“the…“the ’930 patent”), and 9,248,191 (“the ’191 patent”). Those patents are listed in the “Orange Book,” …’930 patents. Allergan later amended its complaint to include the ’191 patent after that patent issued… I. BACKGROUND This patent infringement action arises from Abbreviated New	External link to document
2016-08-05	165	Reply to Claim Construction Brief	Famy Care Limited The asserted patents U.S. Patent 8,629,111 (ECF No. 155-1); …eye . . . .” See, e.g., ’162 patent, cl. 1; ’048 patent, cl. 1; ’191 patent, cl. 1. Applying the adverb… U.S. Patent 8,633,162 (ECF No. 155-2); U.S. Patent 8,642,556 (ECF… U.S. Patent 8,648,048 (ECF No. 155-4); U.S. Patent 8,685,930 (ECF…prosecution history, the patents-in-suit are not novel or innovative. Rather, the patents—which are all directed	External link to document
2016-12-12	214	Memorandum & Opinion	terms of the six patents at issue in this case, U.S. Patent Nos. 8,629,111 (“the ’111 patent”); 8,633,162…Petition for Inter Partes Review of U.S. Patent No. 8,629,111, Case No. IPR2016-01128 (June 3, 2016), …See ’162 patent, claim 14; ’556 patent claims 1, 13-15; ’048 patent, claims 13-16; ’191 patent, claims…8,633,162 (“the ’162 patent”); 8,642,556 (“the ’556 patent”); 8,648,048 (“the ’048 patent”); 8,685,930 (“the…the ’162 patent; claims 1, 11, and 13 of the ’556 patent; and claims 1 and 17 of the ’191 patent. The term	External link to document
2017-01-11	250	Memorandum & Opinion	rejected. Those applications issued as U.S. Patent Nos. 8,629,111; 8,633,162; 8,642,556; and 8,648,048. The…CsA Phase 3 Study Group.” See, e.g., U.S. Patent No. 8,629,111, col. 1, ll. 48- 52 (emphasis added).. …defrauded the U.S. Patent and Trademark Office in order to obtain allowance of the patents in suit.” Teva… U.S. Patent No. 8,685,930. Two years later, the PTO issued the last of the six related patents in suit…procedural question not specific to patent law or bearing on substantive patent law issues, so the law of the	External link to document